Transplant Surgery Research
Clinical and Bio-Analytics Transplant Laboratory (CBATL) of the University of Washington Department of Surgery provides analytical and interpretative expertise that facilitates discoveries with high clinical impact. CBATL is a “think tank” for improving transplant patient care. To improve transplant care, it is our belief that the best skill to have is “asking the right question”. Our “team” of critical thinkers and working with other investigators is the best way to ask the right questions. Members of CBATL brainstorm research ideas to pursue, prioritize and select projects, and for those with expertise in a specific area of a project to provide project management skills to oversee that project to completion. MORE
Stephen C. Rayhill, MD— “A 24-month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs. mycophenolate with standard calicnerurin inhibitor in de novo renal transplantation—Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM).” Novartis Pharmaceutical Corporation. Co-investigator IRB #47855 Trial Protocol CRAD001A244. 8/6/14-12/31/2018, $226,674
“A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant (ReGIFT).” Quark Pharmaceuticals, Inc. 2016- present
James D. Perkins, MD and Jorge D. Reyes, MD— “Genomic Analysis of Hepatoblastoma in Children: Pilot study to identify specific genes indicating recurrence after treatment for hepatoblastoma for future longitudinal studies.” Gerber Foundation. 12/2/2013-11/30/16 $144,839
Kling CE, Perkins JD, Sibulesky L. Three-year follow-up of aviremic hepatitis C-positive kidneys. Am J Transplant. 2019;19(11):3212‐3213. doi:10.1111/ajt.15544
Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. Am J Transplant. 2017;17(11):2863‐2868. doi:10.1111/ajt.14386
Kling CE, Perkins JD, Carithers RL, Donovan DM, Sibulesky L. Recent trends in liver transplantation for alcoholic liver disease in the United States. World J Hepatol. 2017;9(36):1315‐1321. doi:10.4254/wjh.v9.i36.1315
Kling CE, Perkins JD, Sibulesky L. Three-year follow-up of aviremic hepatitis C-positive kidneys. Am J Transplant. 2019 Nov;19(11):3212-3213. doi: 10.1111/ajt.15544. Epub 2019 Aug 23.
Stein EJ, Shivaram GM, Koo KSH, Dick AAS, Healey PJ, Monroe EJ. Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. Pediatr Radiol. 2019 Sep;49(10):1344-1353. doi: 10.1007/s00247-019-04458-6. Epub 2019 Jul 4.
Perkins JD, Dick AA, Healey PJ, Montenovo MI, Biggins SW, Sibulesky L, Reyes JD. New Evidence Supporting Increased Use of Split Liver Transplantation. Transplantation. 2019 Jun 27. doi: 10.1097/TP.0000000000002853. [Epub ahead of print]
Kling CE, Perkins JD, Biggins SW, Johnson CK, Limaye AP, Sibulesky L. Listing practices and graft utilization of hepatitis C-positive deceased donors in liver and kidney transplant. 2019 Jul;166(1):102-108. doi: 10.1016/j.surg.2019.03.015. Epub 2019 May 6.
Stewart J, Snoeyenbos Newman G, Jain R, Bryan A, Berger H, Montenovo M, Bakthavatsalam R, Kling CE, Sibulesky L, Shalhub S, Limaye AP, Fisher CE, Rakita RM. Transplant tourism complicated by life-threatening New Delhi metallo-β-lactamase-1 infection. Am J Transplant. 2019 Apr;19(4):1224-1228. doi:
Kling CE, Perkins JD, Reyes JD, Montenovo MI. Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End-Stage Liver Disease Recipients. Liver Transpl. 2019 Apr;25(4):580-587. doi: 10.1002/lt.25073. Epub 2019 Mar 6.10.1111/ajt.15136. Epub 2018 Oct 29.
Butler CR, Perkins JD, Johnson CK, Blosser CD, Bakthavatsalam R, Leca N, Sibulesky L. Burden of excess mortality after implementation of the new kidney allocation system may be borne disproportionately by middle-aged recipients. PLoS One. 2019 Jan 24;14(1):e0210589. doi: 10.1371/journal.pone.0210589. eCollection 2019.